Roche Holding AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
- Introduction
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
An Observational Study in Clinical Practice Management of Patients With Biological Drugs in Monotherapy
- Conditions
- Rheumatoid Arthritis
- First Posted Date
- 2012-08-14
- Last Posted Date
- 2016-04-04
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 210
- Registration Number
- NCT01664117
An Observational Study of Erlotinib (Tarceva) as Second-line Treatment in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer After Failure of Pemetrexed in First-line Therapy
- First Posted Date
- 2012-08-14
- Last Posted Date
- 2015-12-28
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 57
- Registration Number
- NCT01664533
A Single-Center Study of RO5508887 in Healthy Volunteers
- First Posted Date
- 2012-08-14
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 36
- Registration Number
- NCT01664143
An Observational Study of Xeloda (Capecitabine) in Patients With Metastatic Colorectal Cancer, Colon Cancer in the Adjuvant Setting, Advanced Gastric Cancer or Breast Cancer
- First Posted Date
- 2012-08-14
- Last Posted Date
- 2016-05-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 563
- Registration Number
- NCT01664494
Study To Evaluate the Efficacy and Safety Of Bevacizumab, and Associated Biomarkers, In Combination With Paclitaxel Compared With Paclitaxel Plus Placebo as First-line Treatment Of Patients With Her2-Negative Metastatic Breast Cancer
- Conditions
- Metastatic Breast Cancer
- Interventions
- First Posted Date
- 2012-08-13
- Last Posted Date
- 2019-01-22
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 481
- Registration Number
- NCT01663727
- Locations
- 🇺🇸
Univ of Texas Medical Branch, Galveston, Texas, United States
🇺🇸Texas Oncology, P.A., The Woodlands, Texas, United States
🇺🇸Wellmonth Physician Services, Bristol, Virginia, United States
A Study on Spermatogenesis in Male Renal Transplant Recipients Receiving Valganciclovir (Valcyte®) Versus Untreated Matched Controls
- First Posted Date
- 2012-08-13
- Last Posted Date
- 2018-08-31
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 59
- Registration Number
- NCT01663740
- Locations
- 🇺🇸
Tufts Medical Center, Boston, Massachusetts, United States
🇺🇸University of Minnesota, Minneapolis, Minnesota, United States
🇺🇸University of California at San Francisco, San Francisco, California, United States
A Non-Interventional Study in Patients With Moderate to Severe Rheumatoid Arthritis Treated With RoActemra/Actemra (Tocilizumab)
- Conditions
- Rheumatoid Arthritis
- First Posted Date
- 2012-08-13
- Last Posted Date
- 2019-12-10
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 23
- Registration Number
- NCT01663506
A Study of Onartuzumab in Combination With mFOLFOX6 in Participants With Metastatic HER2-Negative and MET-Positive Gastroesophageal Cancer
- Conditions
- Gastric Cancer
- Interventions
- First Posted Date
- 2012-08-10
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 564
- Registration Number
- NCT01662869
A Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate in Patients With Severe Active Rheumatoid Arthritis, Comparing Tapering Versus Maintaining the Methotrexate Dosage
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2012-08-09
- Last Posted Date
- 2016-10-14
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 427
- Registration Number
- NCT01661140
An Observational Study of Avastin (Bevacizumab) in Combination With Paclitaxel in First-Line Treatment in Patients With HER2-Negative Metastatic Breast Cancer
- Conditions
- Breast Cancer
- First Posted Date
- 2012-08-09
- Last Posted Date
- 2017-08-25
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 16
- Registration Number
- NCT01661153
- Locations
- 🇭🇷
Uni Hospital Split; Oncology & Radiotherapy, Split, Croatia
🇭🇷General Hospital Varazdin, Varazdin, Croatia